Found 58 articles
Northpond Ventures’ funds will support commercial menu expansion and completion of FDA clinical trials
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors of AmpliPhi Biosciences Corporation related to the sale of the Company to C3J Therapeutics, Inc.
CBD And Advanced Wellness Company, RESET Bioscience, Debuts New Product With Highest Level Of Purity And Bioavailability
RESET Bioscience, set to disrupt the current CBD market with new liposomal CBD product developed with advanced nanotechnology typically reserved for pharmaceutical giants
Empirical Bioscience, a privately-held developer and manufacturer of enzymes, polymerases, and reagents for Molecular Biology applications, announced that it has achieved ISO 13485:2016 certification for Medical Device and Quality Management Systems, this is an upgrade from their ISO 13485:2003 certificate.
The High-Bind configuration of the EB Pure Total RNA Kit specifically, but reversibly, binds RNA under optimized conditions allowing proteins and other contaminants to be removed
Empirical Bioscience announced today that they have introduced the EB Pure Tissue DNA Kit, a convenient system that allows for the purification of genomic DNA from animal tissue in 20 minutes or less.
Empirical Bioscience’s New EB Pure Plasmid Mini-Prep Kit Offers High-Quality DNA in 30 Minutes or Less
Empirical Bioscience announced the introduction of a new EB Pure Plasmid Mini-Prep Kit today.
Empirical Bioscience announced today that they are now offering the EB Pure PCR Purification Kit. The system streamlines the DNA purification process and offers ample recovery of high-quality DNA.
Empirical Bioscience announced today that they have introduced the EB Pure Agarose Gel Extraction Kit. The set is designed to quickly isolate small DNA fragments (70 bp to 20 kb) from Agarose Gel in just 15 minutes.
Motif Bio plc announced that two iclaprim abstracts have been accepted for presentation at the upcoming American Society For Microbiology (ASM) Microbe 2018 meeting to be held in Atlanta, GA, USA, June 7-11, 2018.
The Antimicrobials Working Group announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations.
The filing of a shelf registration statement is intended to provide the Company with more timely and efficient access to the U.S. capital markets.
This is the first award that the Company has received from the Cystic Fibrosis Foundation.
Motif Bio REVIVE-1 Phase III Study Results with Iclaprim Published in Peer-reviewed Journal, Clinical Infectious Diseases
The positive topline results from this study were announced in April 2017.
The funds will be used to fund pre-commercialisation activities and other corporate activities in preparation for the anticipated US launch of iclaprim in 2019.
Oregon Bioscience Association Release: Oregon’s Life Science Industry On Display: Oregon Bioscience Showcase 2017
Motif BioSciences, Inc. Announces Iclaprim Granted Orphan Drug Designation By FDA For Treatment Of Staphylococcus Aureus Lung Infections In Patients With Cystic Fibrosis